Epic Sciences
  • Home
  • Who We Are
  • What We Do
  • Our Data
    • Select Publications
    • Scientific Posters
  • Clinical Laboratory
  • Biopharma Solutions
  • News & Events
  • Careers
  • Contact
 

Our data

Our platform is like no other. It’s an enrichment free and unbiased approach for detecting and analyzing all classes of CTCs—even those with rare occurrence. In addition, individual CTCs are molecularly characterized at the single cell level to provide a complete view of each patient’s disease state throughout the course of their treatment.

Read our Publications Here

04.26.2017

06.04.2016

11.06.2016

Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival

Association of AR-V7 on Circulating Tumor Cell as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-Resistant Prostate Cancer

 
 

View our Posters Here

06.02.2017

10.05.2016

01.06.2016

Baseline Circulating Tumor Cell (CTC) Subtype Predicts Response to Enzalutamide but Not Abiraterone in Metastatic Castration-Resistance Prostate Cancer (mCRPC) Patients

Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifier in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 Trial

Single CTC Chacterization Identifies Phenotypic and Genomic Heterogeneity as a Mechanism of Resistance to AR Signaling Directed Therapies (AR Tx) in mCRPC Patients

 
 

EPIC SCIENCES

[email protected]

858.356.6610

LEGAL AND REGULATORY

CAREERS

Copyright© 2017 Epic Sciences